Allogene Therapeutics (NASDAQ:ALLO) Given Outperform Rating at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $10.00 price target on the stock.

Several other equities analysts have also recently commented on ALLO. Piper Sandler reduced their target price on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Friday. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.40.

Allogene Therapeutics Trading Up 2.6 %

Allogene Therapeutics stock opened at $1.94 on Friday. The stock has a market cap of $406.76 million, a P/E ratio of -1.24 and a beta of 1.02. The stock has a 50 day moving average of $1.94 and a 200-day moving average of $2.32. Allogene Therapeutics has a 52 week low of $1.32 and a 52 week high of $4.89.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06. As a group, equities analysts predict that Allogene Therapeutics will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Allogene Therapeutics

In other Allogene Therapeutics news, insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the sale, the insider now directly owns 250,713 shares in the company, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. The trade was a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 52,710 shares of company stock worth $92,125. 24.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Allogene Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Cibc World Markets Corp acquired a new stake in Allogene Therapeutics in the fourth quarter worth about $26,000. PAX Financial Group LLC bought a new stake in shares of Allogene Therapeutics during the 4th quarter worth about $27,000. RPO LLC acquired a new stake in shares of Allogene Therapeutics in the 4th quarter worth approximately $31,000. Caption Management LLC bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at approximately $32,000. Finally, Syon Capital LLC bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at approximately $39,000. 83.63% of the stock is currently owned by institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).